Recombinant Mouse PRMT5 Protein

• Cat.No.: PRMT5-13419M
• Product Overview: Recombinant Mouse PRMT5 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Mouse
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 ºC for short term. For long term storage, store it at -20 ºC～-80 ºC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Prmt5 protein arginine N-methyltransferase 5 [ Mus musculus ]
• Official Symbol: PRMT5
• Gene ID: 27374
• mRNA Refseq: NM_013768.3
• Protein Refseq: NP_038796.2
• UniProt ID: Q8CIG8

Reviews

02/18/2023

Great performance in ELISA.

11/01/2018

Its purity and functionality ensure precise and reproducible results, enabling me to achieve my research objectives with confidence.

10/30/2016

The PRMT5 protein demonstrates exceptional quality, making it an ideal candidate to fulfill my experimental requirements.

Q&As

Are there any ongoing clinical trials targeting PRMT5?

Yes, there are ongoing clinical trials investigating the efficacy of PRMT5 inhibitors in various cancer types.

How does PRMT5 affect cellular differentiation?

PRMT5 influences cellular differentiation by regulating the expression of genes involved in the process.

Can PRMT5 inhibitors be used in combination therapies?

Yes, there is interest in exploring combination therapies involving PRMT5 inhibitors with other anticancer agents to enhance treatment efficacy.

How does PRMT5 contribute to epigenetic regulation?

PRMT5 methylates histone proteins, leading to changes in chromatin structure and gene expression, thus playing a crucial role in epigenetic regulation.

How does PRMT5 influence neurodegenerative diseases?

PRMT5 has been implicated in neurodegenerative diseases, and understanding its role may provide insights into developing therapies for conditions like Alzheimer's and Parkinson's disease.